Daunorubicin hydrochloride is an antibiotic of the family of anthracyclines used in hematocancerology.1 Its encapsulation in liposomes enables better diffusion and higher concentration in the tumoral lesions and reduction of the dosage, thus limiting the drug's toxicity. Phase 1 and 2 studies have demonstrated the good tolerance and efficacy of liposomal daunorubicin hydrochloride, 40 mg/m2 every 15 days, in lesions caused by Kaposi sarcoma (KS).1 We discuss a phase 2 study concerning the efficacy of liposomal daunorubicin in patients with cutaneous and/or visceral KS.
In 1992, an open, noncomparative phase 2 study was carried out in patients with the acquired immunodeficiency syndrome (AIDS) with evolving cutaneous and/or visceral KS. Prior to the initiation of treatment, 5 cutaneous KS lesions were chosen as control lesions. The bronchopulmonary damage was evaluated by means of a bronchofibroscopic and/or a chest computed tomographic scan. The digestive lesions were identified by
Fournier S, Dupont B, Pialoux G, Eliaszewicz M, Gonzalez-Canali G, Feuillie V. Efficacy and Tolerance of Liposomal Daunorubicin in Kaposi Sarcoma Associated With Human Immunodeficiency Virus Infection. Arch Dermatol. 1997;133(7):918-919. doi:10.1001/archderm.1997.03890430140026